Enhancement of FIP in cats immunised with vaccinia virus recombinants expressing CCV and TGEV spike glycoproteins.
Chalmers
W S
WS
Intervet (UK) Ltd., UK.
Horsburgh
B C
BC
Baxendale
W
W
Brown
T D
TD
D000281:Administration, Intranasal; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D000936:Antigen-Antibody Complex / Q000276:immunology; D000956:Antigens, Viral / Q000276:immunology*; D002415:Cats; D017939:Coronavirus, Canine / Q000276:immunology*; D016765:Coronavirus, Feline / Q000276:immunology / Q000472:pathogenicity*; D000939:Epitopes / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D007279:Injections, Subcutaneous; D008562:Membrane Glycoproteins / Q000276:immunology*; D064370:Spike Glycoprotein, Coronavirus; D005760:Transmissible gastroenteritis virus / Q000276:immunology*; D014611:Vaccination / Q000009:adverse effects*; D014614:Vaccines, Synthetic / Q000633:toxicity*; D014616:Vaccinia virus; D014759:Viral Envelope Proteins / Q000276:immunology*; D014765:Viral Vaccines / Q000633:toxicity*; D014774:Virulence
D000914:Antibodies, Viral; D000936:Antigen-Antibody Complex; D000956:Antigens, Viral; D000939:Epitopes; D007074:Immunoglobulin G; D008562:Membrane Glycoproteins; D064370:Spike Glycoprotein, Coronavirus; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines